Title: The role of the chondrocyte in osteoarthritis
Abstract: Arthritis & RheumatismVolume 43, Issue 9 p. 1916-1926 Special ArticleFree to Read The role of the chondrocyte in osteoarthritis Mary B. Goldring, Corresponding Author Mary B. Goldring Beth Israel Deaconess Medical Center, New England Baptist Bone & Joint Institute, and Harvard Medical School, Boston, MassachusettsNew England Baptist Bone & Joint Institute, Harvard Institutes of Medicine, Room 246, 4 Blackfan Circle, Boston, MA 02115Search for more papers by this author Mary B. Goldring, Corresponding Author Mary B. Goldring Beth Israel Deaconess Medical Center, New England Baptist Bone & Joint Institute, and Harvard Medical School, Boston, MassachusettsNew England Baptist Bone & Joint Institute, Harvard Institutes of Medicine, Room 246, 4 Blackfan Circle, Boston, MA 02115Search for more papers by this author First published: 26 March 2001 https://doi.org/10.1002/1529-0131(200009)43:9<1916::AID-ANR2>3.0.CO;2-ICitations: 500AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat REFERENCES 1 Mayne R, Brewton RG. Extracellular matrix of cartilage: collagen. In: JF Woessner, HowellDS, editors. Joint cartilage degradation: basic and clinical aspects. New York: Marcel Dekker; 1993. p. 81–108. 2 Poole AR. Cartilage in health and disease. In: WJ Koopman, editor. Arthritis and allied conditions: a textbook of rheumatology. Baltimore: Williams and Wilkins; 1997. p. 255–308. 3 Hardingham TE, Fosang AJ. Proteoglycans: many forms and many functions. FASEB J 1992; 6: 861–70. 4 Heinegard D, Saxne T, Lorenzo P. Noncollagenous proteins: glycoproteins and related molecules. In: MJ Seibel, SP Robins, JP Bilezekian, editors. Dynamics of bone and cartilage metabolism. New York: Academic Press; 1999. p. 59–69. 5 Akesson K. Osteoarthritis and degenerative spine pathologies. In: MJ Seibel, SP Robins, JP Bilezekian, editors. Dynamics of bone and cartilage metabolism. New York: Academic Press; 1999. p. 637–48. 6 Radin EL, Burr DB, Caterson B, Fyhrie D, Brown TD, Boyd RD. Mechanical determinants of osteoarthrosis. Semin Arthritis Rheum 1991; 21: 12–21. 7 Hughes CE, Caterson B, Fosang AJ, Roughley PJ, Mort JS. Monoclonal antibodies that specifically recognize neoepitope sequences generated by ‘aggrecanase’ and matrix metalloproteinase cleavage of aggrecan: application to catabolism in situ and in vitro. Biochem J 1995; 305: 799–804. 8 Billinghurst RC, Dahlberg L, Ionescu M, Reiner A, Bourne R, Rorabeck C, et al. Enhanced cleavage of type II collagen by collagenases in osteoarthritic articular cartilage. J Clin Invest 1997; 99: 1534–45. 9 Lark MW, Bayne EK, Flanagan J, Harper CF, Hoerrner LA, Hutchinson NI, et al. Aggrecan degradation in human cartilage: evidence for both matrix metalloproteinase and aggrecanase activity in normal, osteoarthritic, and rheumatoid joints. J Clin Invest 1997; 100: 93–106. 10 Ishiguro N, Ito T, Ito H, Iwata H, Jugessur H, Ionescu M, et al. Relationship of matrix metalloproteinases and their inhibitors to cartilage proteoglycan and collagen turnover: analyses of synovial fluid from patients with osteoarthritis. Arthritis Rheum 1999; 42: 129–36. 11 Lohmander LS, Ionescu M, Jugessur H, Poole AR. Changes in joint cartilage aggrecan after knee injury and in osteoarthritis. Arthritis Rheum 1999; 42: 534–44. 12 Hembry RM, Bagga MR, Reynolds JJ, Hamblen DL. Immunolocalisation studies on six matrix metalloproteinases and their inhibitors, TIMP-1 and TIMP-2, in synovia from patients with osteo- and rheumatoid arthritis. Ann Rheum Dis 1995; 54: 25–32. 13 Okada Y, Shinmei M, Tanaka O, Naka K, Kimura A, Nakanishi I, et al. Localization of matrix metalloproteinase 3 (stromelysin) in osteoarthritic cartilage and synovium. Lab Invest 1992; 66: 680–90. 14 Clark IM, Powell LK, Ramsey S, Hazleman BL, Cawston TE. The measurement of collagenase, tissue inhibitor of metalloproteinases (TIMP), and collagenase–TIMP complex in synovial fluids from patients with osteoarthritis and rheumatoid arthritis. Arthritis Rheum 1993; 36: 372–9. 15 Dean DD, Martel-Pelletier J, Pelletier JP, Howell DS, Woessner JF Jr. Evidence for metalloproteinase and metalloproteinase inhibitor imbalance in human osteoarthritic cartilage. J Clin Invest 1989; 84: 678–85. 16 Mitchell PG, Magna HA, Reeves LM, Lopresti-Morrow LL, Yocum SA, Rosner PJ, et al. Cloning, expression, and type II collagenolytic activity of matrix metalloproteinase-13 from human osteoarthritic cartilage. J Clin Invest 1996; 97: 761–8. 17 Shlopov BV, Lie W-R, Mainardi CL, Cole AA, Chubinskaya S, Hasty KA. Osteoarthritic lesions: involvement of three different collagenases. Arthritis Rheum 1997; 40: 2065–74. 18 Imai K, Ohta S, Matsumoto T, Fujimoto N, Sato H, Seiki M, et al. Expression of membrane-type I matrix metalloproteinase and activation of progelatinase A in human osteoarthritic cartilage. Am J Pathol 1997; 151: 245–56. 19 Knauper V, Lopez-Otin C, Smith B, Knight G, Murphy G. Biochemical characterization of human collagenase-3. J Biol Chem 1996; 271: 1544–50. 20 Dahlberg L, Billinghurst RC, Manner P, Nelson F, Webb G, Ionescu M, et al. Selective enhancement of collagenase-mediated cleavage of resident of type II collagen in cultured osteoarthritic cartilage and arrest with a synthetic inhibitor that spares collagenase 1 (matrix metalloproteinase 1). Arthritis Rheum 2000; 43: 673–82. 21 Fosang AJ, Last K, Neame PJ, Murphy G, Knauper V, Tschesche H, et al. Neutrophil collagenase (MMP-8) cleaves at the aggrecanase site E373-A374 in the interglobular domain of cartilage aggrecan. Biochem J 1994; 304: 347–51. 22 Buttner FH, Hughes CE, Margerie D, Lichte A, Tschesche H, Caterson B, et al. Membrane type 1 matrix metalloproteinase (MT1-MMP) cleaves the recombinant aggrecan substrate rAgg1mut at the ‘aggrecanase’ and the MMP sites: characterization of MT1-MMP catabolic activities on the interglobular domain of aggrecan. Biochem J 1998; 333: 159–65. 23 Lark MW, Gordy JT, Weidner JR, Ayala J, Kimura JH, Williams HR, et al. Cell-mediated catabolism of aggrecan: evidence that cleavage at the “aggrecanase” site (Glu373-Ala374) is a primary event in proteolysis of the interglobular domain. J Biol Chem 1995; 270: 2550–6. 24 Tortorella MD, Burn TC, Pratta MA, Abbaszade I, Hollis JM, Liu R, et al. Purification and cloning of aggrecanase-1: a member of the ADAMTS family of proteins. Science 1999; 284: 1664–6. 25 Abbaszade I, Liu RQ, Yang F, Rosenfeld SA, Ross OH, Link JR, et al. Cloning and characterization of ADAMTS11, an aggrecanase from the ADAMTS family. J Biol Chem 1999; 274: 23443–50. 26 Hurskainen TL, Hirohata S, Seldin MF, Apte SS. ADAM-TS5, ADAM-TS6, and ADAM-TS7, novel members of a new family of zinc metalloproteases: general features and genomic distribution of the ADAM-TS family. J Biol Chem 1999; 274: 25555–63. 27 Aigner T, Gluckert K, von der Mark K. Activation of fibrillar collagen synthesis and phenotypic modulation of chondrocytes in early human osteoarthritic cartilage lesions. Osteoarthritis Cartilage 1997; 5: 183–9. 28 Aigner T, Dudhia J. Phenotypic modulation of chondrocytes as a potential therapeutic target in osteoarthritis: a hypothesis. Ann Rheum Dis 1997; 56: 287–91. 29 Aigner T, Zhu Y, Chansky HH, Matsen FA III, Maloney WJ, Sandell LJ. Reexpression of type IIA procollagen by adult articular chondrocytes in osteoarthritic cartilage. Arthritis Rheum 1999; 42: 1443–50. 30 Dayer J-M, Russell RGG, Krane SM. Collagenase production by rheumatoid synovial cells: stimulation by a human lymphocyte factor. Science 1977; 195: 181–3. 31 Dingle JT, Saklatvala J, Hembry R, Tyler J, Fell HB, Jubb R. A cartilage catabolic factor from synovium. Biochem J 1979; 184: 177–80. 32 Saklatvala J, Pilsworth LM, Sarsfield SJ, Gavrilovic J, Heath JK. Pig catabolin is a form of interleukin 1: cartilage and bone resorb, fibroblasts make prostaglandin and collagenase, and thymocyte proliferation is augmented in response to one protein. Biochem J 1984; 224: 461–6. 33 Goldring MB. Degradation of articular cartilage in culture: regulatory factors. In: JF Woessner J H r DS owell, editors. Joint cartilage degradation: basic and clinical aspects. New York: Marcel Dekker; 1993. p. 281–345. 34 Arend WP, Dayer J-M. Inhibition of the production and effects of interleukin-1 and tumor necrosis factor α in rheumatoid arthritis. Arthritis Rheum 1995; 38: 151–60. 35 Westacott CI, Sharif M. Cytokines in osteoarthritis: mediators or markers of joint destruction? Semin Arthritis Rheum 1996; 25: 254–72. 36 Goldring MB. The role of cytokines as inflammatory mediators in osteoarthritis: lessons from animal models. Connect Tissue Res 1999; 40: 1–11. 37 Webb GR, Westacott CI, Elson CJ. Chondrocyte tumor necrosis factor receptors and focal loss of cartilage in osteoarthritis. Osteoarthritis Cartilage 1997; 5: 427–37. 38 Martel-Pelletier J, McCollum R, DiBattista J, Faure M-P, Chin JA, Fournier S, et al. The interleukin-1 receptor in normal and osteoarthritic human articular chondrocytes: identification as the type I receptor and analysis of binding kinetics and biologic function. Arthritis Rheum 1992; 35: 530–40. 39 Feldman M, Bondeson J, Brennan FM, Foxwell BMJ, Maini RN. The rationale for the current boom in anti-TNFα treatment: is there an effective means to define therapeutic targets for drugs that provide all the benefits of anti-TNFα and minimize hazards? Ann Rheum Dis 1999; 58: 127–31. 40 Evans CH, Robbins PD, Ghivizzani SC, Herndon JH, Kang R, Bahnson AB, et al. Clinical trial to assess the safety, feasibility, and efficacy of transferring a potentially anti-arthritic cytokine gene to human joints with rheumatoid arthritis. Hum Gene Ther 1996; 7: 1261–80. 41 Evans CH, Ghivizzani SC, Kang R, Muzzonigro T, Wasko MC, Herndon JH, et al. Gene therapy for rheumatic diseases. Arthritis Rheum 1999; 42: 1–16. 42 Van den Berg WB, Joosten LA, Kollias G, van de Loo FA. Role of tumour necrosis factor α in experimental arthritis: separate activity of interleukin 1β in chronicity and cartilage destruction. Ann Rheum Dis 1999; 58: 140–8. 43 Caron JP, Fernandes JC, Martel-Pelletier J, Tardif G, Mineau F, Geng C, et al. Chondroprotective effect of intraarticular injections of interleukin-1 receptor antagonist in experimental osteoarthritis: suppression of collagenase-1 expression. Arthritis Rheum 1996; 39: 1535–44. 44 Jacques C, Bereziat G, Humbert L, Corvol M, Olivier JL, Masliah J, et al. Post-transcriptional effect of IGF-I on IL-1β-induced type II secreted phospholipase A2 gene expression in rabbit articular chondrocytes. J Clin Invest 1997; 99: 1864–72. 45 Clancy RM, Amin AR, Abramson SB. The role of nitric oxide in inflammation and immunity. Arthritis Rheum 1998; 41: 1141–51. 46 Goldring MB, Berenbaum F. Human chondrocyte culture models for studying cyclooxygenase expression and prostaglandin regulation of collagen gene expression. Osteoarthritis Cartilage 1999; 7: 386–8. 47 Lotz M. The role of nitric oxide in articular cartilage damage. Rheum Dis Clin North Am 1999; 25: 269–82. 48 Amin AR, Attur M, Patel RN, Thakker GD, Marshall PJ, Rediske J, et al. Superinduction of cyclooxygenase-2 activity in human osteoarthritis-affected cartilage: influence of nitric oxide. J Clin Invest 1997; 99: 1231–7. 49 Jacques C, Sautet A, Moldovan M, Thomas B, Humbert L, Berenbaum F. Cyclooxygenase activity in chondrocytes from osteoarthritic and healthy cartilage. Rev Rhum Engl Ed 1999; 66: 701–4. 50 Studer R, Jaffurs D, Stefanovic-Racic M, Robbins PD, Evans CH. Nitric oxide in osteoarthritis. Osteoarthritis Cartilage 1999; 7: 377–9. 51 Hashimoto S, Takahashi K, Amiel D, Coutts RD, Lotz M. Chondrocyte apoptosis and nitric oxide production during experimentally induced osteoarthritis. Arthritis Rheum 1998; 41: 1266–74. 52 Kuhn K, Hashimoto S, Lotz M. IL-1β protects human chondrocytes from CD95-induced apoptosis. J Immunol 2000; 164: 2233–9. 53 Goldring MB, Suen L-F, Yamin R, Lai W-FT. Regulation of collagen gene expression by prostaglandins and interleukin-1β in culture chondrocytes and fibroblasts. Am J Ther 1996; 3: 9–16. 54 Lewis AJ, Manning AM. New targets for anti-inflammatory drugs. Curr Opin Chem Biol 1999; 3: 489–94. 55 Badger AM, Cook MN, Lark MW, Newman-Tarr TM, Swift BA, Nelson AH, et al. SB203580 inhibits p38 mitogen-activated protein kinase, nitric oxide production, and inducible nitric oxide synthase in bovine cartilage-derived chondrocytes. J Immunol 1998; 161: 467–73. 56 Ding GJF, Fischer PA, Boltz RC, Schmidt JA, Colaianne JJ, Gough A, et al. Characterization and quantitation of NF-κB nuclear translocation induced by interleukin-1 and tumor necrosis factor-α. J Biol Chem 1998; 273: 28897–905. 57 Shalom-Barak T, Quach J, Lotz M. Interleukin-17-induced gene expression in articular chondrocytes is associated with activation of mitogen-activated protein kinases and NF-κB. J Biol Chem 1998; 273: 27467–73. 58 Martel-Pelletier J, Mineau F, Jovanovic D, Di Battista JA, Pelletier J-P. Mitogen-activated protein kinase and nuclear factor κB together regulate interleukin-17–induced nitric oxide production in human osteoarthritic chondrocytes: possible role of transactivating factor mitogen–activated protein kinase–activated protein kinase (MAPKAPK). Arthritis Rheum 1999; 42: 2399–409. 59 Mengshol JA, Vincenti MP, Coon CI, Barchowsky A, Brinckerhoff CE. Interleukin-1 induction of collagenase 3 (matrix metalloproteinase 13) gene expression in chondrocytes requires p38, c-Jun N-terminal kinase, and nuclear factor κB: differential regulation of collagenase 1 and collagenase 3. Arthritis Rheum 2000; 43: 801–11. 60 Ridley SH, Sarsfield SJ, Lee JC, Bigg HF, Cawston TE, Taylor DJ, et al. Actions of IL-1 are selectively controlled by p38 mitogen-activated protein kinase: regulation of prostaglandin H synthase-2, metalloproteinases, and IL-6 at different levels. J Immunol 1997; 158: 3165–73. 61 Badger AM, Griswold DE, Kapadia R, Blake S, Swift BA, Hoffman SJ, et al. Disease-modifying activity of SB 242235, a selective inhibitor of p38 mitogen-activated protein kinase, in rat adjuvant-induced arthritis. Arthritis Rheum 2000; 43: 175–83. 62 Olee T, Hashimoto S, Quach J, Lotz M. IL-18 is produced by articular chondrocytes and induces proinflammatory and catabolic responses. J Immunol 1999; 162: 1096–100. 63 Saha N, Moldovan F, Tardif G, Pelletier J-P, Cloutier J-M, Martel-Pelletier J. Interleukin-1β–converting enzyme/caspase-1 in human osteoarthritic tissues: localization and role in the maturation of interleukin-1β and interleukin-18. Arthritis Rheum 1999; 42: 1577–87. 64 Schlaak JF, Pfers I, Meyer Zum Buschenfelde KH, Marker-Hermann E. Different cytokine profiles in the synovial fluid of patients with osteoarthritis, rheumatoid arthritis and seronegative spondylarthropathies. Clin Exp Rheumatol 1996; 14: 155–62. 65 Henrotin YE, De Groote DD, Labasse AH, Gaspar SE, Zheng SX, Geenen VG, et al. Effects of exogenous IL-1β, TNFα, IL-6, IL-8 and LIF on cytokine production by human articular chondrocytes. Osteoarthritis Cartilage 1996; 4: 163–73. 66 Cawston TE, Curry VA, Summers CA, Clark IM, Riley GP, Life PF, et al. The role of oncostatin M in animal and human connective tissue collagen turnover and its localization within the rheumatoid joint. Arthritis Rheum 1998; 41: 1760–71. 67 Silacci P, Dayer JM, Desgeorges A, Peter R, Manueddu C, Guerne PA. Interleukin (IL)-6 and its soluble receptor induce TIMP-1 expression in synoviocytes and chondrocytes, and block IL-1-induced collagenolytic activity. J Biol Chem 1998; 273: 13625–9. 68 Guerne PA, Desgeorges A, Jaspar J-M, Relic B, Peter R, Hoffmeyer P, et al. Effects of IL-6 and its soluble receptor on proteoglycan synthesis and NO release by human articular chondrocytes: comparison with IL-1. Modulation by dexamethasone. Matrix Biol 1999; 18: 253–60. 69 Alaaeddine N, Di Battista JA, Pelletier J-P, Kiansa K, Cloutier J-M, Martel-Pelletier J. Inhibition of tumor necrosis factor α–induced prostaglandin E2 production by the antiinflammatory cytokines interleukin-4, interleukin-10, and interleukin-13 in osteoarthritic synovial fibroblasts: distinct targeting in the signaling pathways. Arthritis Rheum 1999; 42: 710–8. 70 Joosten LAB, Lubberts E, Durez P, Helsen MMA, Jacobs MJM, Goldman M, et al. Role of interleukin-4 and interleukin-10 in murine collagen-induced arthritis: protective effect of interleukin-4 and interleukin-10 treatment on cartilage destruction. Arthritis Rheum 1997; 40: 249–60. 71 Müller-Ladner U, Evans CH, Franklin BN, Roberts CR, Gay RE, Robbins PD, et al. Gene transfer of cytokine inhibitors into human synovial fibroblasts in the SCID mouse model. Arthritis Rheum 1999; 42: 490–7. 72 Van den Berg WB. Lessons for joint destruction from animal models. Curr Opin Rheumatol 1997; 9: 221–8. 73 Zheng H, Fletcher D, Kozak W, Jiang M, Hofmann KJ, Conn CA, et al. Resistance to fever induction and impaired acute-phase response in interleukin-1β-deficient mice. Immunity 1995; 3: 9–19. 74 Li P, Allen H, Banerjee S, Franklin S, Herzog L, Johnston C, et al. Mice deficient in IL-1β-converting enzyme are defective in production of mature IL-1β and resistant to endotoxic shock. Cell 1995; 80: 401–11. 75 Ku G, Faust T, Lauffer LL, Livingston DJ, Harding MW. Interleukin-1β converting enzyme inhibition blocks progression of type II collagen-induced arthritis in mice. Cytokine 1996; 8: 377–86. 76 Butler DM, Malfait A-M, Mason LJ, Warden PJ, Kollias G, Maini RN, et al. DBA/1mice expressing the human TNF-α transgene develop a severe, erosive arthritis: characterization of the cytokine cascade and cellular composition. J Immunol 1997; 159: 2867–76. 77 Van de Loo FA, Kuiper S, van Enckevort FH, Arntz OJ, van den Berg WB. Interleukin-6 reduces cartilage destruction during experimental arthritis: a study in interleukin-6-deficient mice. Am J Pathol 1997; 151: 177–91. 78 Van de Loo FA, Arntz OJ, van den Berg WB. Effect of interleukin 1 and leukaemia inhibitory factor on chondrocyte metabolism in articular cartilage from normal and interleukin-6-deficient mice: role of nitric oxide and IL-6 in the suppression of proteoglycan synthesis. Cytokine 1997; 9: 453–62. 79 Reddi AH. Role of morphogenetic proteins in skeletal tissue engineering and regeneration. Nat Biotech 1998; 16: 247–52. 80 Van den Berg WB. The role of cytokines and growth factors in cartilage destruction in osteoarthritis and rheumatoid arthritis. Z Rheumatol 1999; 58: 136–41. 81 Trippel SB. Growth factor actions on articular cartilage. J Rheumatol Suppl 1995; 43: 129–32. 82 Morales TI. The role and content of endogenous insulin-like growth factor-binding proteins in bovine articular cartilage. Arch Biochem Biophys 1997; 343: 164–72. 83 Middleton JF, Tyler JA. Upregulation of insulin-like growth factor I gene expression in the lesions of osteoarthritic human articular cartilage. Ann Rheum Dis 1992; 51: 440–7. 84 Doré S, Pelletier J-P, DiBattista JA, Tardif G, Brazeau P, Martel-Pelletier J. Human osteoarthritic chondrocytes possess an increased number of insulin-like growth factor 1 binding sites but are unresponsive to its stimulation: possible role of IGF-1–binding proteins. Arthritis Rheum 1994; 37: 253–63. 85 Chevalier X, Tyler JA. Production of binding proteins and role of the insulin-like growth factor I binding protein 3 in human articular cartilage explants. Br J Rheumatol 1996; 35: 515–22. 86 Tardif G, Reboul P, Pelletier J-P, Geng C, Cloutier J-M, Martel-Pelletier J. Normal expression of type 1 insulin-like growth factor receptor by human osteoarthritic chondrocytes with increased expression and synthesis of insulin-like growth factor binding proteins. Arthritis Rheum 1996; 39: 968–78. 87 Fernihough JK, Billingham MEJ, Cwyfan-Hughes S, Holly JMP. Local disruption of the insulin-like growth factor system in the arthritic joint. Arthritis Rheum 1996; 39: 1556–65. 88 Sailor LZ, Hewick RM, Morris EA. Recombinant human bone morphogenetic protein-2 maintains the articular chondrocyte phenotype in long-term culture. J Orthop Res 1996; 14: 937–45. 89 Valcourt U, Ronziere MC, Winkler P, Rosen V, Herbage D, Mallein-Gerin F. Different effects of bone morphogenetic proteins 2, 4, 12, and 13 on the expression of cartilage and bone markers in the MC615 chondrocyte cell line. Exp Cell Res 1999; 251: 264–74. 90 Stewart MC, Saunders KM, Burton-Wurster N, Macleod JN. Phenotypic stability of articular chondrocytes in vitro: the effects of culture models, bone morphogenetic protein 2, and serum supplementation. J Bone Miner Res 2000; 15: 166–74. 91 Moldovan F, Pelletier J-P, Hambor J, Cloutier J-M, Martel-Pelletier J. Collagenase-3 (matrix metalloprotease 13) is preferentially localized in the deep layer of human arthritic cartilage in situ: in vitro mimicking effect by transforming growth factor β. Arthritis Rheum 1997; 40: 1653–61. 92 Chambers MG, Bayliss MT, Mason RM. Chondrocyte cytokine and growth factor expression in murine osteoarthritis. Osteoarthritis Cartilage 1997; 5: 301–8. 93 Van Beuningen HM, Glansbeek HL, van der Kraan PM, van den Berg WB. Osteoarthritis-like changes in the murine knee joint resulting from intra-articular transforming growth factor-β injections. Osteoarthritis Cartilage 2000; 8: 25–33. 94 Sellers RS, Peluso D, Morris EA. The effect of recombinant human bone morphogenetic protein-2 (rhBMP-2) on the healing of full-thickness defects of articular cartilage. J Bone Joint Surg Am 1997; 79A: 1452–63. 95 Glansbeek HL, van Beuningen HM, Vitters EL, Morris EA, van der Kraan PM, van den Berg WB. Bone morphogenetic protein 2 stimulates articular cartilage proteoglycan synthesis in vivo but does not counteract interleukin-1α effects on proteoglycan synthesis and content. Arthritis Rheum 1997; 40: 1020–8. 96 Rogachefsky RA, Dean DD, Howell DS, Altman RD. Treatment of canine osteoarthritis with insulin-like growth factor-1 (IGF-1) and sodium pentosan polysulfate. Osteoarthritis Cartilage 1993; 1: 105–14. 97 Mundlos S, Olsen BR. Heritable diseases of the skeleton. Part I. Molecular insights into skeletal development-transcription factors and signaling pathways. FASEB J 1997; 11: 125–32. 98 Mundlos S, Olsen BR. Heritable diseases of the skeleton. Part II. Molecular insights into skeletal development-matrix components and their homeostasis. FASEB J 1997; 11: 227–33. 99 Holderbaum D, Haqqi TM, Moskowitz RW. Genetics and osteoarthritis: exposing the iceberg. Arthritis Rheum 1999; 42: 397–405. 100 De Crombrugghe B, Katzenstein P, Mukhopadhyay K, Lefebvre V, Zhou G, Garofalo S, et al. Transgenic mice with deficiencies in cartilage collagens: possible models for gene therapy. J Rheumatol Suppl 1995; 43: 140–2. 101 Vertel BM. The ins and outs of aggrecan. Trends Cell Biol 1995; 5: 458–64. 102 Horton WE Jr, Lethbridge-Cejku M, Hochberg MC, Balakir R, Precht P, Plato CC, et al. An association between an aggrecan polymorphic allele and bilateral hand osteoarthritis in elderly white men: data from the Baltimore Longitudinal Study of Aging (BLSA). Osteoarthritis Cartilage 1998; 6: 245–51. 103 Jacenko O, Ito S, Olsen BR. Skeletal and hematopoietic defects in mice transgenic for collagen X. Ann N Y Acad Sci 1996; 785: 278–80. 104 Buckwalter JA, Mankin HJ. Articular cartilage repair and transplantation. Arthritis Rheum 1998; 41: 1331–42. 105 Brittberg M, Lindahl A, Nilsson A, Ohlsson C, Isaksson O, Peterson L. Treatment of deep cartilage defects in the knee with autologous chondrocyte transplantation. N Engl J Med 1994; 331: 889–95. 106 Caplan AI, Elyaderani M, Mochizuki Y, Wakitani S, Goldberg VM. Principles of cartilage repair and regeneration. Clin Orthop 1997; 342: 254–72. Citing Literature Volume43, Issue9September 2000Pages 1916-1926 ReferencesRelatedInformation